Valneva (NASDAQ:VALN) Stock Price Up 6%

Valneva SE (NASDAQ:VALN - Get Free Report) shares were up 6% on Wednesday . The stock traded as high as $8.69 and last traded at $8.69. Approximately 913 shares were traded during trading, a decline of 92% from the average daily volume of 11,136 shares. The stock had previously closed at $8.20.

Analysts Set New Price Targets

A number of research firms have recently weighed in on VALN. Guggenheim cut their price objective on Valneva from $18.00 to $17.00 and set a "buy" rating on the stock in a research report on Friday, March 22nd. HC Wainwright reaffirmed a "buy" rating and set a $26.00 price target on shares of Valneva in a report on Wednesday, May 8th.

Valneva Stock Up 6.5 %

The company has a current ratio of 2.64, a quick ratio of 2.22 and a debt-to-equity ratio of 0.84. The stock has a market cap of $607.96 million, a PE ratio of -21.29 and a beta of 2.22. The business has a 50 day moving average of $7.90 and a 200-day moving average of $9.07.

Valneva (NASDAQ:VALN - Get Free Report) last released its quarterly earnings results on Wednesday, March 20th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.20 by ($0.70). The company had revenue of $45.12 million for the quarter, compared to analysts' expectations of $45.06 million. Valneva had a negative return on equity of 14.56% and a negative net margin of 15.88%. Equities research analysts predict that Valneva SE will post -0.28 EPS for the current fiscal year.

Institutional Trading of Valneva

An institutional investor recently raised its position in Valneva stock. General American Investors Co. Inc. lifted its stake in shares of Valneva SE (NASDAQ:VALN - Free Report) by 2.7% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 354,361 shares of the company's stock after purchasing an additional 9,361 shares during the quarter. General American Investors Co. Inc. owned about 0.51% of Valneva worth $2,831,000 at the end of the most recent quarter. Institutional investors and hedge funds own 11.39% of the company's stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.